

Brian T Hill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1811813/publications.pdf>

Version: 2024-02-01

160
papers

9,763
citations

159573

30
h-index

39667

94
g-index

160
all docs

160
docs citations

160
times ranked

9779
citing authors

#	ARTICLE	IF	CITATIONS
1	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	27.0	3,865
2	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	10.7	1,467
3	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2020, 382, 1331-1342.	27.0	1,067
4	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018, 103, 874-879.	3.5	329
5	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , the, 2020, 7, e511-e522.	4.6	201
6	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	3.5	135
7	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 2260-2267.	1.6	132
8	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87
9	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. <i>Blood</i> , 2018, 132, 91-91.	1.4	81
10	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
11	Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2019, 37, 471-480.	1.6	74
12	Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, e295-e298.	3.5	67
13	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	7.0	61
14	Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e344-e351.	2.0	59
15	Ibrutinib–associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non–Hodgkin lymphoma: An observational study. <i>Mycoses</i> , 2019, 62, 1140-1147.	4.0	57
16	Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics. <i>Oncotarget</i> , 2015, 6, 16912-16925.	1.8	53
17	Outcomes of front–line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 1394-1401.	4.1	52
18	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 12-20.	4.9	52

#	ARTICLE	IF	CITATIONS
19	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
20	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucl. <i>Blood</i> , 2021, 137, 1832-1835.	1.4	48
21	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma. <i>Cancer</i> , 2018, 124, 816-825.	4.1	44
22	Brexucabtagene autoleucl for the treatment of relapsed/refractory mantle cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 435-441.	3.1	43
23	miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. <i>Molecular Cancer</i> , 2015, 14, 185.	19.2	42
24	Experience with Axicabtagene Ciloleucl (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CART Consortium. <i>Blood</i> , 2019, 134, 763-763.	1.4	42
25	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 185-217.	4.9	40
26	Defining Incidence, Risk Factors, and Impact on Survival of Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 720-724.	2.0	39
27	Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucl CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Blood</i> , 2019, 134, 245-245.	1.4	37
28	The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. <i>British Journal of Haematology</i> , 2011, 152, 561-569.	2.5	36
29	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 176, 618-628.	2.5	36
30	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <i>Oncologist</i> , 2019, 24, e1236-e1250.	3.7	36
31	Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. <i>Blood</i> , 2014, 124, 2657-2665.	1.4	33
32	Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 989-996.	4.1	33
33	Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1567-1572.	2.0	32
34	Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1184-1187.	2.4	32
35	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. <i>Journal of Critical Care</i> , 2020, 58, 58-64.	2.2	31
36	Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1972-1977.	1.3	29

#	ARTICLE	IF	CITATIONS
37	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	5.2	29
38	Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 1630-1630.	1.4	29
39	The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. <i>British Journal of Haematology</i> , 2013, 163, 72-80.	2.5	28
40	Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 46-52.	1.2	28
41	Aggressive B-Cell Lymphomas With Translocations Involving <i>BCL6</i> and <i>MYC</i> Have Distinct Clinical-Pathologic Characteristics. <i>American Journal of Clinical Pathology</i> , 2014, 142, 339-346.	0.7	27
42	Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2015, 90, 144-148.	4.1	27
43	Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 524-535.	2.5	27
44	Clinical approach to diffuse large B cell lymphoma. <i>Blood Reviews</i> , 2016, 30, 477-491.	5.7	26
45	A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. <i>Blood</i> , 2017, 130, 1676-1679.	1.4	26
46	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	5.2	26
47	Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1414-1427.	4.9	24
48	Extranodal Marginal Zone Lymphoma of Ocular Adnexa: Outcomes following Radiation Therapy. <i>Ocular Oncology and Pathology</i> , 2017, 3, 181-187.	1.0	23
49	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 541-554.	1.6	23
50	Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment. <i>Journal of Leukemia (Los Angeles, Calif)</i> , 2014, 02, .	0.1	22
51	Targeting mTORC1-Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells. <i>Molecular Cancer Research</i> , 2014, 12, 1205-1215.	3.4	22
52	Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 986-993.	1.3	21
53	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	2.4	21
54	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	5.2	21

#	ARTICLE	IF	CITATIONS
55	Pulmonary involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma is a specific pathologic finding independent of inflammatory infiltration. <i>Leukemia and Lymphoma</i> , 2012, 53, 589-595.	1.3	20
56	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1029-1034.	2.0	19
57	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 918-923.	2.5	19
58	Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	4.1	18
59	KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. <i>Blood</i> , 2019, 134, 754-754.	1.4	18
60	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. <i>Haematologica</i> , 2021, 106, 2845-2852.	3.5	18
61	Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. <i>British Journal of Haematology</i> , 2019, 186, 255-262.	2.5	17
62	Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 262-271.	2.0	17
63	Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 170-175.	0.4	17
64	Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEP system. <i>British Journal of Haematology</i> , 2014, 167, 281-285.	2.5	16
65	Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2015, 56, 1552-1553.	1.3	16
66	Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. <i>British Journal of Haematology</i> , 2016, 175, 275-280.	2.5	16
67	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. <i>Blood</i> , 2016, 128, 3222-3222.	1.4	16
68	Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 763-769.	1.3	15
69	Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. <i>Blood Advances</i> , 2019, 3, 132-135.	5.2	15
70	Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. <i>Blood</i> , 2021, 138, 744-744.	1.4	15
71	Effect of bone marrow CD34+ cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 775-781.	2.4	14
72	Nonmyeloablative Second Transplants are Associated with Lower Nonrelapse Mortality and Superior Survival Than Myeloablative Second Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1738-1746.	2.0	13

#	ARTICLE	IF	CITATIONS
73	Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 857-862.	0.4	13
74	2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucef (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. <i>Blood</i> , 2018, 132, 2967-2967.	1.4	13
75	Ionizing radiation exposures in treatments of solid neoplasms are not associated with subsequent increased risks of chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2016, 43, 9-12.	0.8	12
76	Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1640-1648.	1.3	12
77	Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1255-1266.	3.5	11
78	Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2018, 59, 1195-1201.	1.3	11
79	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 3623-3632.	5.2	11
80	A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 360-360.	1.4	11
81	A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies. <i>Blood</i> , 2021, 138, 3868-3868.	1.4	11
82	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	7.0	10
83	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2020, 189, 318-322.	2.5	10
84	Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. <i>Blood</i> , 2015, 126, 719-719.	1.4	10
85	Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax. <i>Blood</i> , 2021, 138, 2628-2628.	1.4	10
86	Acute Myeloid Leukemia: When to Transplant in First Complete Remission. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 101-108.	2.3	9
87	Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Timesâ€œDaily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1588-1595.	2.0	9
88	Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1141-1144.	2.0	9
89	The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population. <i>Leukemia and Lymphoma</i> , 2019, 60, 2899-2908.	1.3	9
90	Late occurrence of progressive multifocal leukoencephalopathy after anti-CD19 chimeric antigen receptor T cell therapy. <i>European Journal of Haematology</i> , 2021, 106, 584-588.	2.2	9

#	ARTICLE	IF	CITATIONS
91	BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1107-1115.	2.0	9
92	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753.	1.4	9
93	Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. <i>Blood</i> , 2021, 138, 429-429.	1.4	9
94	Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2016, 6, 1.	2.7	8
95	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	3.5	8
96	Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 293-300.	1.3	7
97	Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of <scp>PET</scp> scan in treatment planning. <i>British Journal of Haematology</i> , 2017, 179, 674-676.	2.5	7
98	Cardiac Surgery Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1182-1191.	1.3	7
99	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 32-39.	0.9	7
100	A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. <i>Seminars in Hematology</i> , 2021, 58, 35-44.	3.4	7
101	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	1.2	7
102	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1344-1352.	1.3	7
103	Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis. <i>Blood</i> , 2019, 134, 780-780.	1.4	7
104	Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e95-e102.	0.4	6
105	One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 467-476.	3.8	6
106	The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma. <i>Current Oncology Reports</i> , 2019, 21, 44.	4.0	6
107	BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 1553-1561.	2.4	6
108	Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2021, 17, 1295-1310.	2.4	6

#	ARTICLE	IF	CITATIONS
109	Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Blood</i> , 2021, 138, 165-165.	1.4	6
110	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 581-586.	2.0	5
111	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 757-763.	2.5	5
112	The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 335-343.	1.3	5
113	Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 2860-2860.	1.4	5
114	Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e485-e494.	0.4	5
115	Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 81-87.	2.5	4
116	A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 690-694.	1.3	4
117	Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2522-2526.	2.0	4
118	Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. <i>Blood</i> , 2021, 138, 529-529.	1.4	4
119	Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. <i>Blood</i> , 2021, 138, 3826-3826.	1.4	4
120	Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. <i>OncoTargets and Therapy</i> , 2015, 8, 2391.	2.0	3
121	Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2015, 8, 115-124.	0.9	3
122	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	2.2	3
123	Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era. <i>Blood</i> , 2019, 134, 4567-4567.	1.4	3
124	Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Passé or Yet?. <i>HemaSphere</i> , 2019, 3, e275.	2.7	2
125	A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 32-34.	1.4	2
126	Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 1973-1973.	1.4	2

#	ARTICLE	IF	CITATIONS
127	A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 3728-3728.	1.4	2
128	High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 1555-1555.	1.4	2
129	Unbiased Metabolomic Screening Reveals Pre-Existing Plasma Signatures in Large B-Cell Lymphoma Patients Treated with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cells: Association with Cytokine Release Syndrome (CRS) and Neurotoxicity (ICANS). <i>Blood</i> , 2020, 136, 42-43.	1.4	2
130	Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel. <i>Blood</i> , 2020, 136, 38-39.	1.4	2
131	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. <i>Cancers</i> , 2022, 14, 791.	3.7	2
132	Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies. <i>British Journal of Haematology</i> , 0, , .	2.5	2
133	Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 827-831.	2.0	1
134	Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 48-52.	0.4	1
135	Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 1-2.	1.4	1
136	The PI3K Inhibitor GS-1101 (CAL-101) Synergistically Potentiates HDAC-Induced Proliferation Inhibition and Apoptosis Through the Activation of JNK in Lymphoma Cells. <i>Blood</i> , 2012, 120, 3714-3714.	1.4	1
137	Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status. <i>Blood</i> , 2019, 134, 5248-5248.	1.4	1
138	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥ 65 Years Receiving Bendamustine-Rituximab. <i>Blood</i> , 2021, 138, 3517-3517.	1.4	1
139	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021, 138, 2637-2637.	1.4	1
140	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG) Tj ETQq0 00rgBT /Overlock 10	1.4	1
141	Gene Expression and Epigenetic Analysis in Relapsed/Refractory Diffuse Large B Cell Lymphoma Provides Insights into Evolution of Treatment Resistance to R-CHOP. <i>Blood</i> , 2020, 136, 26-26.	1.4	1
142	Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma. <i>Blood</i> , 2020, 136, 24-25.	1.4	1
143	Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 1031-1033.	2.4	1
144	Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211044.	0.9	1

#	ARTICLE	IF	CITATIONS
145	It's Personal: Achieving Optimal Busulfan Exposure for All Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1149-1150.	2.0	0
146	Descriptive comparison of hospital formulary decisions with published oncology valuation methods. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 891-905.	0.9	0
147	Molecular Subtype Characterization of Formalin-Fixed, Paraffin-Embedded Diffuse Large B-Cell Lymphoma Samples on the Iceplex® System.. <i>Blood</i> , 2012, 120, 2705-2705.	1.4	0
148	Tandem Autologous Hematopoietic Progenitor Cell Transplantation (AHPCT) for High-Risk Hodgkin Lymphoma: Mature Results of a Prospective Trial. <i>Blood</i> , 2012, 120, 1990-1990.	1.4	0
149	Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 4666-4666.	1.4	0
150	Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1226-1226.	1.4	0
151	Quantitative Assessment of the Evolution of Therapeutic Target Antigen Expression Level in Diffuse Large B-Cell Lymphoma in Response to Treatment. <i>Blood</i> , 2021, 138, 4367-4367.	1.4	0
152	Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis. <i>Blood</i> , 2021, 138, 1451-1451.	1.4	0
153	Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. <i>Blood</i> , 2020, 136, 34-35.	1.4	0
154	Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
155	Outcomes of Active Surveillance Versus Initial Treatment for Nodular Lymphocyte Predominant Hodgkin Lymphoma: A National Cancer Database (NCDB) Analysis of 2,480 Patients. <i>Blood</i> , 2020, 136, 29-30.	1.4	0
156	Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
157	Integrative DNA Methylation and Gene Expression Analysis Reveals Candidate Biomarkers Associated with Dichotomized Response to Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-22.	1.4	0
158	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study. <i>Blood</i> , 2020, 136, 1-3.	1.4	0
159	Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. <i>European Journal of Haematology</i> , 2022, , .	2.2	0
160	Abstract 1262: Gender bias in the association of pre-treatment cytokine signatures with response and survival in B cell lymphoma patients treated with anti-CD19 CAR T-cell therapy. <i>Cancer Research</i> , 2022, 82, 1262-1262.	0.9	0